jeudi 8 juin 2017

Onco Actu du 8 juin 2017

1. Biologie

New possible target for cancer treatment [Karolinska Institutet]

4.2 Dép., diag. & prono. - Génome

New report evaluates cost effectiveness of exome sequencing [PHG Foundation]

European NGS Service Providers Prepare to Leverage Growing Demand for Exome and RNA Sequencing [Frost & Sullivan]

NCI-MATCH cancer trial reaches 6,000-patient tumor sequencing goal two years early [ECOG-ACRIN]

4.9 Dép., diag. & prono. - Sein

Some Small Tumors In Breasts May Not Be So Bad After All [NPR]

Mammograms: Are we overdiagnosing small tumors? [Yale Cancer Center]

5.10 Traitements - Essais

Carlisle’s statistics bombshell names and shames rigged clinical trials [ForBetterScience]

5.12 Immunothérapies

New Class of Double-Duty Magnetic Nanoparticles Engineered to Lower Cancer’s Defenses While Firing up Immune System [Johns Hopkins]

5.12.2 Immunothérapies - CAR-T

Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL [Novartis]

As Novartis preps for first CAR-T FDA AdComm, Juliet data revealed [FierceBiotech]

Novartis’s Next Challenge: Pricing Breakthrough Cancer Treatment [Bloomberg]

Novartis posts landmark CAR-T data as head-to-head rivalry with Kite Pharma looms [EndPoints]

Blood and bone marrow therapies grab spotlight at world's top cancer meeting [Reuters]

Novartis touts new T-cell therapy data in race for FDA approval [Reuters]

5.12.5 Immunothérapies - Pharma

Bristol-Myers' new Opdivo spot asks, 'Who wouldn't want a chance to live longer?'[FiercePharma]

5.2 Pharma

Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma [Seattle Genetics]

5.2.1 Pharma - Partenariats

Genentech axes its $1B-plus IDO drug deal with NewLink in the wake of underwhelming data [EndPoints]

NewLink Genetics to Regain Rights to GDC-0919 [NewLink]

5.2.3 Pharma - économie

Johnson & Johnson's New Prostate Cancer Drug Might Make Pfizer Sick [The Street]

5.4 Traitements - Economie

Value-based drug pricing makes sense, but is difficult to pull off [STAT]

When Drugs Cost Too Much [Science-Based Medicine]

5.5 ASCO

ASCO soundbites: Weekend insights from some of pharma's finest oncology wordsmiths [FiercePharma]

8 things doctors are buzzing about at the biggest cancer meeting [Washington Post] ASCO (général) - Industriels

ASCO17: AstraZeneca pumps up expectations on near-term cancer drug wins, looking to shed a rep for failure [EndPoints]

5.5.12 ASCO (médico-éco)

High drug costs (and stock values) take center stage at final day of ASCO [HealthNewsReview]

5.5.13 ASCO (divers)

How yoga could ease cancer patients' pain and fatigue [The Guardian]

5.5.2 ASCO (sein)

ASCO 2017: BRCA-targeting drug olaparib offers hope for women with advanced breast cancer with inherited mutation [Institute of Cancer Research]

5.5.4 ASCO (immunothérapies)

CAR T-cell therapy — Why it’s too soon to speculate about a ‘cure’ for multiple myeloma [HelathNewsReview]

CAR T-Cell Trials Boast Promising Results [The Scientist]

5.5.5 ASCO (gastro-intestinal)

Less Chemotherapy May Be Best Choice for Some Patients with Colon Cancer, Study Shows [NCI]

6. Lutte contre les cancers

Critics challenge NIH finding that bigger labs aren’t necessarily better [Science]

6.1 Observation

Report Looks at Liver Cancer, Fastest-Growing Cause of Cancer Death in U.S. [ACS]

6.6 Publications

How to avoid the stigma of a retracted paper? Don't call it a retraction [Science]